Armand Butera

Investigators also reported an increase in individualized FeNO associated with young female patients.

Investigators incorporated a myriad of studies detailing the anxiety and depression associated with the disease, and offered new insights into the concerns of patients and caregivers.

A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.

Adult patients with moderate-to-severe atopic dermatitis reported incremental improvement of their condition in a new extension trial study presented at EADV.

Investigators reported that the vaccine prevented symptomatic and severe cases of COVID-19 in several populations including older patients.

Investigators reported that the drug helped improve skin repigmentation in patients with vitiligo, but added that further studies were needed to fully explore its efficacy.

Additionally, investigators believe epidermal impairment in the skin of children with atopic dermatitis could contribute to the development of allergic sensitization.

Investigators believed the immunosuppressive qualities of these biologics posed no additional risk in contracting the COVID-19 virus, but added that additional research is warranted.

Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.

Acknowledging the potential medical harm from errors and bias, investigators believe clinical AI needs to be held to a higher standard.

Dr. Castro considers it to be a fruitful and exciting time in the study of asthma-modifying therapy, with some biologic therapies achieving control in patients with severe asthma.

Investigators believe these findings can help identify high-risk groups and prevent exacerbations through tailored treatments.

Dr. Castro talks of the available biologic therapies that can be used to treat asthma and other respiratory disorders.

Investigators found that exposure to surgical smoke and disinfectants over a long period of time led to increased risk of COPD in US female nurses.

Two study authors speak on providing pediatric patients of color with atopic diseases with greater access to care.

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.

The drug is approved for adults and pediatric patients 12 years and older after the failure of 1 or 2 lines of systemic therapy.

In his recent presentation, Dr. Sperling spoke of how a greater focus needed to be made on the implementation of cardiovascular care strategies, as well as better utilization of health system approaches.

Dr. Castro defines type 2 inflammation and the complications surrounding severe asthma, as well as several biomarkers including IgE levels, blood eosinophils, and exhaled nitric oxide.

The approval follows recent phase 3 trial data showing significant improvement in patient-reported outcomes for the treatment of atopic dermatitis.

An Australian study used data consistent with international literature on the subject of de-labeling penicillin for low-risk allergy patients.

As predicted, previous asthma during early childhood was a strong risk factor for asthma in young adulthood.

Investigators report that few medical schools in Europe consider allergology to be an important area of study, resulting in a lack of knowledge regarding certain allergy practices.

Though well-tolerated and highly efficacious, the biologic was linked several adverse events in pediatric patients with atopic dermatitis including facial erythema and herpes simplex virus.

In this episode of Derm Discussions, vitiligo expert John Harris, MD, PhD, discusses new tactics and therapeutic options in treating inflammatory skin disorders like vitiligo, alopecia areata, and atopic dermatitis.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Dr. Papadopoulos reports on new phase 3 data from the LIBERTY VOYAGE ASTHMA study on patients aged 6-11 with moderate-to-severe asthma.

Dr. Ezhkova and fellow investigators found that low UV exposure prompted an increase in pigmentation production through melanocytes in the body.

Dr. Javed Butler referenced several promising ongoing trials of diabetes-related medications and their effects on heart disease but added that unclear guidelines kept them from being properly acknowledged.

Though select diabetes guidelines suggest the use of continuous glucose monitoring on patients with diabetic patients on intensive therapy, the potential benefits on type 2 patients without insulin and pre-diabetes patients has yet to be fully explored.